Experience with eyelid-sparing orbital exenteration: the 2000 Tullos O. Coston Lecture.
Abstract
[PURPOSE] To provide data on types of lesions that require orbital exenteration and discuss our experience with exenteration, emphasizing the eyelid-sparing technique.
[METHODS] The records were reviewed on all patients who underwent orbital exenteration by the senior author and his colleagues. The underlying disease, method of exenteration, healing times, complications, cosmetic outcome, local tumor control, and patient survival were analyzed.
[RESULTS] Of 56 orbital exenterations, 47 were done by eyelid-sparing technique and 9 by eyelid-sacrificing technique. The 9 tumors of eyelid origin that required exenteration included basal cell carcinoma (4), sebaceous gland carcinoma (3), squamous cell carcinoma (1), and melanoma (1). Four of the eyelid lesions were managed by the eyelid-sparing technique and 5 by the eyelid-sacrificing method. The 24 tumors of conjunctival origin included melanoma (20) and squamous cell carcinoma (4). The eyelid-sparing method was used in 22 of the 24 cases. The 10 primary orbital lesions included melanoma (3), malignant lacrimal gland tumor (3), a rhabdoid tumor, meningioma, Wegener's granulomatosis, and aspergillosis. The eyelid-sparing method was used in 8 of the 10 cases. Among intraocular tumors were uveal melanomas (10) and retinoblastoma (1). The eyelid sparing method was used in all 11. With the eyelid-sparing technique, the mean time from exenteration to wound healing and readiness for a prosthesis was 4 weeks (median, 2 weeks; range, 2 to 24 weeks). With the eyelid-sacrificing technique, the mean time was 68 weeks (median, 34 weeks; range, 2 to 340 weeks). Complications were few and cosmetic results were satisfactory. Local tumor control with exenteration was achieved in 53 of 56 cases, but metastasis occurred in 11 of 20 cases of conjunctival melanoma (55%) and in 6 of 10 patients with uveal melanoma (60%). Metastasis has developed in none of the 3 patients with malignant epithelial tumors of lacrimal gland origin.
[CONCLUSIONS] Orbital exenteration is an appropriate procedure for orbital involvement by unresectable malignant tumors of the eyelids, conjunctiva, intraocular structures, and orbit. In most of these cases, including about half of tumors originating in the eyelids, an eyelid-sparing exenteration can be used to achieve more rapid healing.
[METHODS] The records were reviewed on all patients who underwent orbital exenteration by the senior author and his colleagues. The underlying disease, method of exenteration, healing times, complications, cosmetic outcome, local tumor control, and patient survival were analyzed.
[RESULTS] Of 56 orbital exenterations, 47 were done by eyelid-sparing technique and 9 by eyelid-sacrificing technique. The 9 tumors of eyelid origin that required exenteration included basal cell carcinoma (4), sebaceous gland carcinoma (3), squamous cell carcinoma (1), and melanoma (1). Four of the eyelid lesions were managed by the eyelid-sparing technique and 5 by the eyelid-sacrificing method. The 24 tumors of conjunctival origin included melanoma (20) and squamous cell carcinoma (4). The eyelid-sparing method was used in 22 of the 24 cases. The 10 primary orbital lesions included melanoma (3), malignant lacrimal gland tumor (3), a rhabdoid tumor, meningioma, Wegener's granulomatosis, and aspergillosis. The eyelid-sparing method was used in 8 of the 10 cases. Among intraocular tumors were uveal melanomas (10) and retinoblastoma (1). The eyelid sparing method was used in all 11. With the eyelid-sparing technique, the mean time from exenteration to wound healing and readiness for a prosthesis was 4 weeks (median, 2 weeks; range, 2 to 24 weeks). With the eyelid-sacrificing technique, the mean time was 68 weeks (median, 34 weeks; range, 2 to 340 weeks). Complications were few and cosmetic results were satisfactory. Local tumor control with exenteration was achieved in 53 of 56 cases, but metastasis occurred in 11 of 20 cases of conjunctival melanoma (55%) and in 6 of 10 patients with uveal melanoma (60%). Metastasis has developed in none of the 3 patients with malignant epithelial tumors of lacrimal gland origin.
[CONCLUSIONS] Orbital exenteration is an appropriate procedure for orbital involvement by unresectable malignant tumors of the eyelids, conjunctiva, intraocular structures, and orbit. In most of these cases, including about half of tumors originating in the eyelids, an eyelid-sparing exenteration can be used to achieve more rapid healing.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 해부 | eyelid
|
눈꺼풀 | dict | 14 | |
| 해부 | melanoma (1
|
scispacy | 1 | ||
| 해부 | conjunctival
|
scispacy | 1 | ||
| 해부 | conjunctiva
|
scispacy | 1 | ||
| 해부 | intraocular
|
scispacy | 1 | ||
| 합병증 | eyelid-sparing orbital
|
scispacy | 1 | ||
| 합병증 | lesions
|
scispacy | 1 | ||
| 합병증 | eyelid-sparing
|
scispacy | 1 | ||
| 합병증 | eyelid lesions
|
scispacy | 1 | ||
| 합병증 | orbital lesions
|
scispacy | 1 | ||
| 합병증 | wound
|
scispacy | 1 | ||
| 합병증 | eyelids
|
scispacy | 1 | ||
| 합병증 | orbit
|
scispacy | 1 | ||
| 합병증 | eyelid-sparing exenteration
|
scispacy | 1 | ||
| 질환 | tumor
|
C0027651
Neoplasms
|
scispacy | 1 | |
| 질환 | tumors
|
C0027651
Neoplasms
|
scispacy | 1 | |
| 질환 | basal cell carcinoma
|
C0007117
Basal cell carcinoma
|
scispacy | 1 | |
| 질환 | sebaceous gland carcinoma
|
C0206684
Sebaceous Adenocarcinoma
|
scispacy | 1 | |
| 질환 | squamous cell carcinoma
|
C0007137
Squamous cell carcinoma
|
scispacy | 1 | |
| 질환 | melanoma
|
C0025202
melanoma
|
scispacy | 1 | |
| 질환 | conjunctival
|
C0009758
conjunctiva
|
scispacy | 1 | |
| 질환 | primary orbital lesions
|
scispacy | 1 | ||
| 질환 | rhabdoid tumor
|
C0206743
Rhabdoid Tumor
|
scispacy | 1 | |
| 질환 | meningioma
|
C0025286
Meningioma
|
scispacy | 1 | |
| 질환 | Wegener's granulomatosis
|
C3495801
Granulomatosis with polyangiitis
|
scispacy | 1 | |
| 질환 | aspergillosis
|
C0004030
Aspergillosis
|
scispacy | 1 | |
| 질환 | intraocular tumors
|
scispacy | 1 | ||
| 질환 | uveal melanomas
|
C0220633
Uveal melanoma
|
scispacy | 1 | |
| 질환 | retinoblastoma
|
C0035335
Retinoblastoma
|
scispacy | 1 | |
| 질환 | conjunctival melanoma
|
C0346360
Malignant melanoma of conjunctiva
|
scispacy | 1 | |
| 질환 | uveal melanoma
|
C0220633
Uveal melanoma
|
scispacy | 1 | |
| 질환 | malignant epithelial tumors
|
C0007097
Carcinoma
|
scispacy | 1 | |
| 질환 | unresectable malignant tumors
|
C1336869
Unresectable Malignant Neoplasm
|
scispacy | 1 | |
| 질환 | sebaceous gland carcinoma (3
|
scispacy | 1 | ||
| 질환 | squamous cell carcinoma (1
|
scispacy | 1 | ||
| 질환 | squamous cell carcinoma (4)
|
scispacy | 1 | ||
| 질환 | melanoma (3
|
scispacy | 1 | ||
| 질환 | malignant lacrimal gland tumor (3
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | patient
|
scispacy | 1 | ||
| 기타 | retinoblastoma (1)
|
scispacy | 1 | ||
| 기타 | lacrimal gland
|
scispacy | 1 |
MeSH Terms
Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Eyelids; Female; Humans; Infant; Male; Middle Aged; Orbit Evisceration; Orbital Neoplasms; Surgery, Plastic; Time Factors; Wound Healing
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Penetrating globe injury following periocular hyaluronic acid filler injection: A case report.
- Application of the SCIA-Pure Skin Perforator Flap in Bilateral Upper Eyelid Reconstruction: A Case Report and Review of the Literature.
- Combined minimally invasive lymphatic microsurgery and aligned nanofibrillar collagen scaffold for refractory post-traumatic eyelid lymphedema: A case report.
- Orbicularis Oculi Toxin Injection for Treating Levator Palpebrae Superioris Weakness: Clinical Effect and Safety in a Cohort Study.
- Correction of tear trough deformity in young patients without eyebags using orbital fat reposition and release of tear trough ligament.